TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00394043

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: A protocol of specific Osteopathic manipulative techniques was used.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sub-Therapeutic Ultrasound
Description: Sub-therapeutic ultrasound was applied in a standardized method.
Study: NCT02077829

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Illness Management and Recovery
Description: Evidence-based practice given individually or in groups, weekly for 10-12 months.
Study: NCT02048137

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Study: NCT02110680

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sports TENS 2
Description: transcutaneous electric stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sports TENS 2
Description: transcutaneous electric stimulation
Study: NCT01891617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and diets
Description: Exercise and high-fat diet Exercise and high-carbohydrate diet Sedentary and high-fat diet Sedentary and high-carbohydrate diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and diets
Description: Exercise and high-fat diet Exercise and high-carbohydrate diet Sedentary and high-fat diet Sedentary and high-carbohydrate diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and diets
Description: Exercise and high-fat diet Exercise and high-carbohydrate diet Sedentary and high-fat diet Sedentary and high-carbohydrate diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and diets
Description: Exercise and high-fat diet Exercise and high-carbohydrate diet Sedentary and high-fat diet Sedentary and high-carbohydrate diet
Study: NCT02632669

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hemigland focal LDR brachytherapy
Description: The treatment is limited to the hemigland that has been diagnosed with unilateral low to intermediate risk prostate cancer by means of pre-treatment staging with mpMRI and transperineal template biopsy. The affected hemigland will be treated with iodine-125 to a prescription dose of 145Gy. Patients will be assessed at baseline and subsequently at 6 weeks, 3, 6, 9, 12,18, 24 months after treatment with PSA and EN2 measurements and validated questionnaires relating to erectile, urinary, and bowel function and general health related quality of life. mpMRI and transperineal template biopsy will be performed 24 months after treatment.
Study: NCT02950155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: A single infusion at a dose of 500 mg Mabthera/Rituximab.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sodium Chloride solution
Description: A single infusion of Placebo/Sham.
Study: NCT03523416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Atrial Shunt System
Description: Transcatheter treatment of symptomatic left heart failure patients
Study: NCT03784911

Intervention type: DEVICE
Intervention: SOZO Device
Description: SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. SOZO measurements will be performed before the start of cancer treatment, at the 1/4, 1/2, and 3/4 time points of treatment, and after completion of treatment. Participants be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes.

Intervention type: DEVICE
Intervention: DEXA Scan
Description: DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
Study: NCT02191657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: Oral iron chelator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: Oral iron chelator
Study: NCT03740139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Police-Mental Health Linkage System
Description: When, during an encounter, the police officer decides to call the number provided in the notice, the Linkage Specialist (a licensed mental health provider from the mental health service where the subject was recruited, who has access to the clinic's EMR) can provide telephonic support to the officer.
Study: NCT05193890

Intervention type: GENETIC
Intervention: retrospective analysis of a panel result
Description: retrospective analysis of a exome clinical solution

Intervention type: GENETIC
Intervention: retrospective analysis of a panel result
Description: retrospective analysis of a exome clinical solution

Intervention type: GENETIC
Intervention: retrospective analysis of a panel result
Description: retrospective analysis of a exome clinical solution
Study: NCT03201744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients will be randomized to moderate (TOF 1-2) or deep (post tetanic count 1-2) relaxation. Low pressure insufflation (start pressure set at 8 mm Hg)
Description: All procedures will start with low insufflation pressure (8 mmHg). Surgical field assessment (scale 1-5) will be performed every 5 minutes (Martini Br J Anaesth 2014). If conditions are poor (rating 1-2), intraperitoneal insufflation will be incrementally increased (10 mmHg, 12 mmHg, 15 mmHg) every 5 minutes as needed.Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
Study: NCT02708160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Free toothpaste
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride Free toothpaste
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride Free toothpaste
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.1% Fluoride toothpaste
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.1% Fluoride toothpaste
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1.1% Fluoride toothpaste
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.243% Fluoride toothpaste
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.243% Fluoride toothpaste
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.243% Fluoride toothpaste
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
Study: NCT03961581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Using electric car
Description: Child will use little electric cars to go to the reception of operating theatre to operating room.
Study: NCT02664753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 56 days of weight-adjusted L-Carnitine treatment
Description: Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.~Day 1: a first bolus of 6g of L-Carnitine is administered with a syringe driver of 50 ml.~Day 2 to Day 10: Two mini-perfusions are prepared each day, corresponding to 1 administration every 12 hours. 50 mg/kg/day (rounded up to the next gram) L-Carnitine is added to each syringes~For the next 46 days, patients will take oral doses of L-Carnitine as follows:~\< à 60kg : 2g/day \> 60kg : 3g/day If the patient leaves the hospital before D10, oral treatment can be initiated at the end of the hospitalization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10 days of intravenous placebo (isotonic saline)
Description: Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).~Day 1: 1 50ml syringe driver of 50 ml isotonic saline solution . Day 2 to Day 10 : Two syringe drivers of 50 ml of isotonic saline solution are prepared each day, one during the morning and one during the evening.
Study: NCT02498860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemebit
Description: 500mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
Study: NCT04221009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI and CBT 4-session manualized intervention
Description: This is a 4-session intervention derived from Motivational Interviewing and Cognitive Behavior Therapy and adapted with cognitive accommodations.
Study: NCT02264197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBX 245 CL - fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBX 245 CL- fasted
Study: NCT03192254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-monitoring
Description: recording fruit and vegetable consumption

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-monitoring
Description: recording fruit and vegetable consumption

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self-monitoring
Description: recording fruit and vegetable consumption

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: daily monetary incentives
Description: daily payments for consuming fruits and vegetables

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: delayed lump sum monetary incentives
Description: lump sum payments for consuming fruits and vegetables
Study: NCT03667261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sealing Socket Abutment
Description: Sealing Socket Abutment (SSA) serves as a mechanical barrier to isolate the grafted area, stabilize the clot and contain the graft material, and seal the socket from foreign contaminants and also minimizing the risk of premature loading of the implant during healing. By preparing an SSA fabricated to follow the transmucosal contours of the natural tooth, the grafted area can be sealed and separated from the growth of soft tissue without the use of a membrane or releasing incisions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cover screw
Description: immediate implant placement in mandibular molar area will be covered with conventional cover screw
Study: NCT00572702

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal fixation Amreich-Richter
Description: Descending vaginal cuff will be treated with fixation of the cuff on sacrospinous ligament

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolift total
Description: Descending vaginal cuff will be treated with insertion of site-specific mesh into the vesico-vaginal and recto-vaginal space
Study: NCT01779401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 150mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100mg
Study: NCT01314456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviGo
Description: Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
Study: NCT01779401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100mg
Study: NCT03695250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDO1 Inhibitor BMS-986205
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT02906059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study: NCT04388189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: FDA approved antidepressant
Study: NCT04992000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4-free app + PHN intervention
Description: same mentioned in groups
Study: NCT04388189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: FDA approved antidepressant
Study: NCT02498314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grade I-II SZ mobilization
Description: Hip grade I-IISZ traction in a resting position is applied using gentle repetitive traction movements during 10 minutes. The mean peak force applied is 2,71N (S.D= 0,94), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grade II TZ mobilization
Description: Hip grade IITZ traction in a resting position is applied during 10 minutes. The traction force is applied during 45 seconds with 15 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 5.94 N (S.D= 1), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grade III mobilization
Description: Hip grade III traction in a resting position is applied during 10 minutes. The traction force is applied during 30 seconds with 30 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 7.04 N (S.D= 0.32), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
Study: NCT00990236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin dose adjusted Lovenox based on TEG
Description: Enoxaparin doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R \< 1.0 min - increase dose by 10 mg BID; delta-R \>/= 1.0 min and \</= 2.0 min - no change; delta-R \> 2.0 min - decrease dose by 10 mg BID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 30 mg BID
Description: Enoxaparin dose of 30 mg twice a day without any adjustments
Study: NCT01489488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: Single oral dose of 2.4 milligram (mg) riociguat (BAY63-2521) as pediatric high-concentration suspension (0.15 mg per milliliter \[mg/mL\], i.e. 16 mL) under fasting conditions
Study: NCT02191657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: Oral iron chelator
Study: NCT00058773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion of EBV Specific Cytotoxic T-Lymphocytes
Description: EBV specific cytotoxic T-lymphocytes will be given by intravenous injection over 1-10 minutes.~Each patient will receive two injections, 14 days apart.
Study: NCT04270890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal compression belt system
Description: The abdominal compression belt system is provided free of charge from CDR systems, Canada.~The belt has specifically been chosen from other similar devices commercially available as it is independent of other immobilisation devices and can be used with the patient located within a full body vacbag as per current immobilisation position.
Study: NCT04776720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Practice Program
Description: 3 month group yoga classes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Conditioning Program
Description: 3 month group physical conditioning classes
Study: NCT03503097

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Provide saliva samples

Intervention type: OTHER
Intervention: Genetic Counseling
Description: Undergo counseling

Intervention type: OTHER
Intervention: Genetic Testing
Description: Undergo genetic testing

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Complete questionnaire
Study: NCT02988947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNE+HyP
Description: This is a combined PNE and Hypnosis psychological intervention. PNE is a cognitive based approach that highlights the biopsychosocial model of pain and focuses on neurophysiological and neurobiological processes and pain representation. Hypnosis aims at promoting pain control, increasing positive coping strategies, and targeting positive psychological variables.
Study: NCT02371460

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA-rich algal oil
Description: Mothers will receive a DHA-rich algal oil treatment (400 mg DHA per capsule) three times a day before meals from randomization (\<72 hours post-delivery) until the infant reaches 36 weeks PMA.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mothers will receive a placebo capsule three times a day before meals from randomization (\<72 hours post-delivery) until the infant reaches 36 weeks PMA.
Study: NCT02723552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 40 minute aerobic exercise sessions 3x/week.
Study: NCT02177734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N9 vaccine GSK3277510A
Description: One dose of GSK3277510A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277510A H7N9 vaccine administered IM in the deltoid region of dominant arm at Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N9 vaccine GSK3277510A
Description: One dose of GSK3277510A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277510A H7N9 vaccine administered IM in the deltoid region of dominant arm at Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N9 vaccine GSK3277510A
Description: One dose of GSK3277510A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277510A H7N9 vaccine administered IM in the deltoid region of dominant arm at Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N9 vaccine GSK3277510A
Description: One dose of GSK3277510A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277510A H7N9 vaccine administered IM in the deltoid region of dominant arm at Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N9 vaccine GSK3277509A
Description: One dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of dominant arm at Day 21

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of placebo administered IM at the deltoid region of dominant arm at Day 21
Study: NCT02058550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Receive reminder email survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Receive reminder email survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer-assisted intervention
Description: Receive reminder email survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer-assisted intervention
Description: Receive reminder email survey
Study: NCT02604368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC411
Description: Soft gelatin capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft gelatin capsule